Traditional medical practice in the world has maintained its popularity in spite of the challenges of the rapid development of modern medicine. The World Health Organization observed that 80% of world population still rely on traditional practices of special cultural heritages. In Asia, the traditional practices include mainly that of the Middle East, India and China. The 3000 years of development in the three different regions has resulted in cross-cultural influences and exchanges, particularly revealed in the rich collections of medicinal herbs. Ayurveda medicine has well maintained its traditional philosophy and practice. It has enjoyed very substantial governmental support on the national level and has remained popular. Traditional Chinese Medicine, likewise, has kept its popularity and vibrance. However, with the ever advancing modern medicine which is giving efficient acute care and specific solutions to known target areas of clinical concern, are unavoidable obstacles to an integrative practice. Besides India, China is the only country in the world where Traditional Medicine is still playing a major role in national health care. During the COVID-19 pandemic both Ayurveda and Chinese Medicine practitioners tried hard to contribute by offering integrative treatment to the infected patients. They were getting a lot of national and professional endorsements. One would speculate that with this unknown virus and diverse clinical presentations, a better integrative program would be able to provide better outcome. On the prevention side, medicinal herbs are expected to be able to boost up the innate immunity of the individual so that infection could be better resisted. Given the similarities between the Indian and Chinese Systems of traditional practice, it is suggested that Ayurveda and Chinese Medicine could develop a joint mission with combined efforts, to collaborate in research and trials, with the aim of consolidating Integrative Practice. This article concentrates on the Indian and Chinese areas of traditional practice, viz. Ayurveda and Chinese Medicine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105209 | PMC |
http://dx.doi.org/10.1016/j.jaim.2022.100591 | DOI Listing |
Cardiovasc Toxicol
January 2025
The Second Department of Cardiovascular Medicine, Baoji People's Hospital, Baoji, China.
Dihydromyricetin (Dih), a naturally occurring flavonoid, has been identified to exert a protective effect against ischemia/reperfusion injury. However, the detailed mechanisms remain unclear. Here we investigated the biological role of Dih in preventing hypoxia/reoxygenation (H/R) injury in cardiomyocytes.
View Article and Find Full Text PDFInt Urol Nephrol
January 2025
Department of Nephrology, Jiangxi Medical College, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Purpose: To clarify the causal association between cardiovascular proteins and diabetic nephropathy (DN) in Europeans.
Methods: The large genome-wide association study data of cardiovascular proteins and DN were used for this two-sample Mendelian randomization (MR) analysis. We took the Inverse variance weighted (IVW) as the primary method.
Discov Oncol
January 2025
Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, Jiangsu, China.
This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). The relationship between CTAs expression and progression-free survival (PFS) was assessed.
View Article and Find Full Text PDFCytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFJ Perianesth Nurs
January 2025
Department of Gynecology, the First Hospital of Lanzhou University, Lanzhou, China.
Purpose: This study aims to evaluate the effect of acupoint application on the prevention of postoperative sore throat (POST), cough, expectoration, hoarseness, and patient satisfaction after general anesthesia.
Design: Randomized controlled trial.
Methods: A randomized double-blind clinical trial was designed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!